Results for total cohort:MG-ADL responders in cycle 1: 68% vs. 37%, OR: 3.70 [95% CI: 1.85–7.58] (P < 0.001)Results for AChR+ patients:MG-ADL responders in cycle 1: 68% vs. 30%, OR: 4.95 (95% CI: 2.21–11.53) (P < 0.001)QMG responders in cycle 1: 63% vs. 14%, OR: 10.84 (95% CI: 4.18–31.20) (P < 0.001). This evidence concerns the gene SGCA and myasthenia gravis.